ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Dr. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, as well as Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research, at MD Anderson.

Dr. Yee will focus on identifying T cells that strongly bind and kill tumor cells expressing an undisclosed target antigen. Then the T cell receptors (TCRs) will be sequenced and their corresponding DNA will be placed into stem cells to create preclinical therapeutic candidates for further evaluation.  The ultimate goal of this work is to enable a clinical program based on hematopoietic stem cells that are isolated from the patient, engineered in the lab and then returned to the patient to create a population of antigen-specific killer T cells that target and kill the tumor. ImmunoCellular’s Stem-to-T-cell platform technology has the potential to overcome the issue of short-lived T cell responses seen with the present forms of T cell and CAR-T therapies.

“The work on which Dr. Yee and ImmunoCellular are collaborating is both exciting in what it represents for immuno-oncology, and potentially groundbreaking, as it has not previously been accomplished on a large scale,” said Steven Swanson, PhD, ImmunoCellular Senior Vice President, Research. “The identification of novel TCR sequences for application in stem cells has the potential to launch this program toward clinical testing. We are privileged to be working with an immune-oncologist of Dr. Yee’s stature, and believe that this work has the potential to position our Stem-to-T-cell program as one of the most promising in the industry.”

“With our lead phase 3 program ICT-107 underway and financed, we are now focusing additional resources and attention on moving our Stem-to-T-cell program toward clinical development,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “Our collaboration with Dr. Yee and MD Anderson is an important step in our efforts to build a leading cancer immunotherapy company, and we look forward to potentially establishing more collaborations and bringing additional promising technologies into ImmunoCellular.” (Original Source)

Shares of ImmunoCellular closed yesterday at $0.47. IMUC has a 1-year high of $1.03 and a 1-year low of $0.35. The stock’s 50-day moving average is $0.43 and its 200-day moving average is $0.46.

On the ratings front, Roth Capital analyst Joseph Pantginis maintained a Buy rating on IMUC, with a price target of $3, in a report issued on September 24. The current price target implies an upside of 538.3% from current levels. According to, Pantginis has a total average return of -3.3%, a 35.8% success rate, and is ranked #3670 out of 3840 analysts.

ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.